GPE
Gilead Sciences Announces Layoffs at California HQ and Closure of Seattle Office
Gilead Sciences, layoffs, California HQ, Seattle office closure, biopharma, workforce reduction
Gilead Sciences and Kite Pharma Announce Layoffs, Closure of Seattle and Philadelphia Offices
Gilead Sciences, Kite Pharma, layoffs, office closures, Seattle, Philadelphia, biotech industry, restructuring
Johnson & Johnson Expands Immunology Portfolio with $1.25B Acquisition of Yellow Jersey Therapeutics
Johnson & Johnson, Yellow Jersey Therapeutics, NM26, atopic dermatitis, bispecific antibody, immunology, Numab Therapeutics
Bayer’s Q3 Earnings Plummet 37%, CEO Urges Patience Amid Performance-Boosting Strategy
Bayer, Q3 earnings, decline, CEO Bill Anderson, performance-boosting strategy, pharmaceuticals, crop science, generics, Xarelto, Nubeqa, Kerendia.
Nkarta Shifts Focus to Autoimmune Diseases, Deprioritizing Cancer Programs
Nkarta, autoimmune diseases, CAR NK cell therapy, NKX019, lupus nephritis, cancer programs, deprioritization
Nektar Therapeutics Sells Alabama Manufacturing Facility and Reagent Business for $90 Million
Nektar Therapeutics, manufacturing site, reagent arm, divestment, Ampersand, $90 million
PrognomiQ Secures $34 Million Funding to Enhance Early Lung Cancer Detection with Multi-Omics Technology
PrognomiQ, lung cancer detection, multi-omics technology, early detection test, funding, series D round
AstraZeneca Advances in Obesity Market with ECC5004 Deal and Promising Clinical Data
AstraZeneca, obesity, ECC5004, GLP-1RA, cardiometabolic diseases, weight loss market
FDA Raises Sterility and Quality Concerns at Mark Cuban’s Dallas Drug Compounding Facility
Mark Cuban, Cost Plus Drugs, FDA, sterility concerns, quality issues, drug compounding, Dallas facility
Leqembi’s Global Sales Reach $67 Million, Yet US Adoption Faces Hurdles
Leqembi, Biogen, Eisai, Alzheimer’s disease, global sales, US adoption challenges